Basiliximab Induction
Basiliximab Induction is a pharmacotherapeutic strategy in liver transplant immunosuppression that belongs to the class of interleukin-2 receptor antagonist (IL-2RA) induction therapies, distinguished by its use of the monoclonal antibody basiliximab to selectively inhibit T-cell activation during the early post-transplant period.
217
Publications
9.1K
Citations
1.6K
Authors
487
Institutions
Publications per year
2017–2026
36
217
Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation
Daniel C. Brennan, John A. Daller, Kathleen D. Lake et al. · New England Journal of Medicine · 2006 · 730 citations · Full text
Medicine, Nephrology, Pharmacology +17
Hélio Tedesco‐Silva, Josette Eris, Julio Pascual et al. · American Journal of Transplantation · 2004 · 257 citations · Full text
Lutz Fischer, J. Klempnauer, Susanne Beckebaum et al. · American Journal of Transplantation · 2012 · 189 citations · Full text
1–5 of 217
1.6K
4
h-index
4
h-index
4
h-index
4
h-index
4
h-index
1–5 of 1.6K
487
Charité - Universitätsmedizin Berlin
Berlin, Germany
9 h-index
44 publications
2K citations
University of Michigan
Ann Arbor, United States
7 h-index
19 publications
3K citations
Emory University
Atlanta, United States
6 h-index
28 publications
1.1K citations

St James's University Hospital
Leeds, United Kingdom
5 h-index
5 publications
192 citations

Washington University in St. Louis
St Louis, United States
5 h-index
9 publications
489 citations
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
5 h-index
26 publications
952 citations
Universität Hamburg
Hamburg, Germany
5 h-index
25 publications
983 citations
University College London
London, United Kingdom
5 h-index
9 publications
285 citations
1–8 of 487
37 publications · 2.1K citations
26
h-index
22 publications · 1.8K citations
21
h-index
39 publications · 783 citations
18
h-index
15 publications · 352 citations
12
h-index
11 publications · 703 citations
11
h-index
1–5